Current Rheumatology Reports

, 15:363

Biomarkers in ANCA-Associated Vasculitis

VASCULITIS (LR ESPINOZA, SECTION EDITOR)

DOI: 10.1007/s11926-013-0363-x

Cite this article as:
Lally, L. & Spiera, R.F. Curr Rheumatol Rep (2013) 15: 363. doi:10.1007/s11926-013-0363-x
Part of the following topical collections:
  1. Topical Collection on Vasculitis

Abstract

Despite recent advances in the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), relapse remains common and patients often experience a variable clinical course after initial treatment. New biomarkers are needed to aid the management of these complex diseases. Discoveries regarding the pathogenesis of AAV, from the importance both of activated B and T cells and the alternative complement pathway to genomic data, may lay the groundwork for identification of novel biomarkers.

Keywords

ANCAAAVANCA-associated vasculitisBiomarkersGranulomatosis with polyangiitisWegener’s granulomatosisMicroscopic polyangiitisComplement

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of RheumatologyHospital for Special SurgeryNew YorkUSA